A live vaccine for VZV exists, marketed as Zostavax. A systematic review by the Cochrane Library concluded that Zostavax can reduce the incidence of<unk><unk>  by almost 50%. A 2007 study found that the<unk>  vaccine is likely to be cost-effective in the U.S., projecting an annual savings of $82 to $103 million in healthcare costs with cost-effectiveness ratios ranging from $16,229 to $27,609 per quality-adjusted life year gained. In October 2007 the vaccine was officially recommended in the U.S. for healthy adults aged 60 and over.
Herpes zoster cost-effectiveness of therapy
Smallpox cost-effectiveness of therapy
Stevens-Johnson syndrome cost-effectiveness of therapy
Leprosy cost-effectiveness of therapy
Leprosy future or investigational therapies
HIV AIDS cost-effectiveness of therapy
Eczema cost-effectiveness of therapy
Bornholm disease cost-effectiveness of therapy